Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by mdjbrownon Oct 17, 2023 9:55am
69 Views
Post# 35686956

RE:RE:RE:An additional 1,378,843 shares of common stock may be ....

RE:RE:RE:An additional 1,378,843 shares of common stock may be ....TTG, I dont think it matters what school anyone attended, as there is very little with this share transfer in lieu of cash that would be considered standard as a shares for debt would have likely been a more strait forward issue.

Take for instance the statement "An additional 1,378,843 shares of common stock may be issuable to MediPharm to the extent the VWAP of Tilray’s common stock for the five trading days ending on October 9, 2023 declines below $2.3958."


The additional shares that may be issuable were actually more shares than initially transferred to Medipharm in the first issue, so what could possibly trigger an event to recieve more shares than initially receiving in the first place. Was there concerns the shareprice would drop more than 50% in those 5 trading days?

Secondly, according to the first prospectus, the proposed price per unit took place at $2.32, so why is higher price of $2.39 the trigger for additional shares


I think there still may be more to this transaction as alleyesonme has suggested, but with Medipharm tight lipped, we will need to see the upcoming financials to decipher that puzzle or wait for additional disclosure from Tilray.

Stay tuned ..........................
<< Previous
Bullboard Posts
Next >>